7 completed, 3 recruiting, 1 active not recruiting, 1 not yet recruiting. 5 Phase 2, 3 Phase 1, 3 Phase 4, 2 Not applicable, 1 Phase 3.
Follow Dry Powder Inhalers: new trials by email Literature Review of Dry Powder Inhalers trials Research Report on Dry Powder Inhalers
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 3 Trial of Inhaled Mosliciguat in PH-ILD (PHrontier) Mosliciguat, Placebo, Dry Powder Inhaler - Pulmonary Hypertension, Interstitial Lung Disease | Phase 3 | Recruiting | Pulmovant, Inc. | 376 | 2026-08-31 | 2026-09-11 |
| A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis LTI-03, Dry Powder Inhaler, Placebo - Idiopathic Pulmonary Fibrosis (IPF) | Phase 2 | Recruiting | Rein Therapeutics | 120 | 2026-02-02 | 2026-10-16 |
| Pressurized Meter Dose Inhaler V/S Dry Powder Inhaler Pressurized Metered Dose Inhaler (pMDI), Dry Powder Inhaler - Asthma (Diagnosis) | Not applicable | Not yet recruiting | University of Health Sciences Lahore | 210 | 2026-02-01 | 2026-01-28 |
| A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD inhaled mosliciguat, Dry Powder Inhaler - Pulmonary Hypertension, Interstitial Lung Disease (ILD) | Phase 2 | Recruiting | Pulmovant, Inc. | 20 | 2025-12-23 | 2026-09-02 |
| A Study of Inhaled AZD8630 in Adolescents With Asthma AZD8630, Dry powder inhaler - Asthma | Phase 1 | Completed | AstraZeneca | 10 | 2025-06-11 | 2025-10-14 |
| A Phase 1 Study of Mosliciguat in Healthy, Adult Males Mosliciguat, 14C mosliciguat, Dry Powder Inhaler - Healthy Volunteer | Phase 1 | Completed | Pulmovant, Inc. | 8 | 2025-06-10 | 2026-06-16 |
| A Study of Mosliciguat in PH-ILD Mosliciguat, Dry Powder Inhaler, Placebo - Pulmonary Hypertension, Interstitial Lung Disease | Phase 2 | Active not recruiting | Pulmovant, Inc. | 135 | 2024-10-29 | 2026-09-10 |
| Nebulizer Versus Dry Powdered Inhalers for Chronic Obstructive Pulmonary Disease (COPD) Nebulizers, Dry Powder Inhaler, Brovana - COPD, COPD Exacerbation | Phase 4 | Terminated | Wake Forest University Health Sciences | 40 | 2017-10-03 | 2021-06-22 |
| Phase 2a, AMP Challenge, Dose Escalation Study to Assess the Dose Response for Topical Efficacy and Systemic Activity in Asthmatic Subjects Fluticasone furoate (FF) Dry Powder Inhaler, Fluticasone propionate (FP) Dry Powder Inhaler, Budesonide (BUD) Turbuhaler - Asthma | Phase 2 | Completed | GlaxoSmithKline | 56 | 2017-02-09 | 2020-07-31 |
| Phase 1 Study of ALZT-OP1 Combination Therapy in Normal Healthy Volunteers ALZT-OP1a, ALZT-OP1b, Dry Powder Inhaler - Healthy Volunteers | Phase 1 | Completed | AZTherapies, Inc. | 26 | 2015-06-01 | 2015-07-21 |
| Use of Mobile Devices and the Internet to Streamline an Asthma Clinical Trial fluticasone/salmeterol 250/50 Dry Powder Inhaler, fluticasone/salmeterol 100/50 Dry Powder Inhaler, fluticasone 100mcg Dry Powder Inhaler - Asthma | Phase 4 | Completed | Nemours Children's Clinic | 108 | 2013-10-01 | 2018-12-19 |
| Comparison of Indacaterol With That of Placebo in 'Maintenance naïve' Patients With COPD Using Blinded Tiotropium as Active Control Indacaterol, Placebo to tiotropium, Tiotropium - Chronic Obstructive Pulmonary Disease (COPD) | Phase 4 | Withdrawn | Novartis Pharmaceuticals | 2012-11-01 | 2017-04-20 | |
| A Study of Mometasone Furoate Metered Dose Inhaler in Children With Persistent Asthma (P04223) Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 25 mcg, Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 50 mcg, Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 100 mcg - Asthma | Phase 2 | Completed | Organon and Co | 583 | 2012-01-25 | 2024-06-17 |
| Dose-response of Inhaled Formoterol Using Methacholine Challenge as a Bioassay formoterol, Dry Powder Inhaler (Twisthaler) - Asthma | Not applicable | Completed | University of Florida | 37 | 2008-03-01 | 2011-12-05 |
Asthma (6) · Lung Diseases, Interstitial (4) · Cardiovascular Diseases (3) · Fibrosis (3) · Hypertension, Pulmonary (3) · Vascular Diseases (3) · Lung Diseases (2) · Pulmonary Disease, Chronic Obstructive (2) · Disease (1) · Idiopathic Pulmonary Fibrosis (1)
Pulmovant, Inc. (4) · AZTherapies, Inc. (1) · AstraZeneca (1) · GlaxoSmithKline (1) · Nemours Children's Clinic (1) · Novartis Pharmaceuticals (1) · Organon and Co (1) · Rein Therapeutics (1) · University of Florida (1) · University of Health Sciences Lahore (1) · Wake Forest University Health Sciences (1)
United States (10) · Germany (3) · United Kingdom (3) · Australia (2) · Poland (2) · Argentina (1) · Belgium (1) · Brazil (1) · Bulgaria (1) · Canada (1) · Czechia (1) · France (1) · Italy (1) · Japan (1) · Latvia (1)
Ubaldo Martin (2) · Ubaldo Martin, MD (2) · David Brazier, BS (1) · David Elmaleh, PhD (1) · Jill A Ohar, MD, FCCP (1) · Kathryn Blake, PharmD (1) · Leslie Hendeles, PharmD (1)
PMID 27740721, PMID 32484940, PMID 37347518
2008 (1), 2016 (1), R01HL114899 (1)